DOES HYDROXYUREA IMPROVE OUTCOMES IN SICKLE CELL PATIENTS EXPERIENCING POST-ACUTE SEQUELAE OF COVID-19 (PASC)? NARRATIVE REVIEW

Background: Sickle cell disease (SCD) patients are particularly vulnerable to severe outcomes from COVID-19, including post-acute sequelae of COVID-19 (PASC). Hydroxyurea, a well-established therapy for SCD, may offer benefits in managing these sequelae. Objective: This narrative review aims to evaluate the potential of Hydroxyurea in improving outcomes for SCD patients experiencing PASC. Methods: A comprehensive literature search was conducted across Embase.com, Medline ALL (Ovid), Web of Science Core Collection, Cochrane Central Register of Controlled Trials (Wiley), and Google Scholar using relevant MeSH terms and keywords. Studies were selected based on their relevance to Hydroxyurea use in SCD and its impact on PASC. Data extraction focused on study characteristics, outcomes, and mechanisms of action. Results:Hydroxyurea has shown efficacy in decreasing the occurrence of vaso-occlusive crises, acute chest syndrome, and the need for blood transfusions in individuals with sickle cell disease. The anti-inflammatory qualities and capacity to stimulate fetal hemoglobin synthesis of this substance indicate potential advantages in alleviating symptoms of PASC, which are often marked by persistent inflammation and respiratory problems. Comparative studies have shown that Hydroxyurea is still considered a fundamental treatment option because of its effectiveness, cost-effectiveness, and well-established safety record. Conclusion: Hydroxyurea shows promise in improving outcomes for SCD patients experiencing PASC, potentially through its anti-inflammatory effects and reduction of sickle cell-related complications. Further longitudinal studies are needed to confirm its long-term benefits and optimize treatment strategies.